Table 1. IV versus SC administration of atezolizumab.
| Characteristics | Atezolizumab | |
|---|---|---|
| IV | SC (thigh) | |
| Formulation | Human IgG1 | Human IgG1 with recombinant hyaluronidase |
| Target | PD-L1 | PD-L1 |
| Dose Q 3 weeks | 1,200 mg | 1,875 mg |
| Pharmacokinetics (2) | ||
| Ctrough μg · d/mL (at the end of cycle 1) [%CV] | 85 [33] | 89 [43] |
| AUC0−21d, ss μg ∙ d/mL [%CV] | 3,328 [20] | 2,907 [32] |
| Total volume, mL | 20 | 15 |
| Pharmacodynamics (2) | ||
| Response rate | 12% | 10% |
| PFS (months) | 2.9 | 2.8 |
| Treatment-emergent anti-atezolizumab antibodies | 13.9% | 19.5% |
| Logistics | ||
| Pharmacy prep time (minutes) | 30 | 0 |
| IV line start (minutes) | 15 | 0 |
| IV infusion time-chair time (minutes) | 30 | 30 (observation) |
| Patient preference | + | +++ |
| Cost of drug | ++ | Unknown |
| Cost of administration | ++ | + |
IV, intravenous; SC, subcutaneous; IgG1, immune globlulin-G1; PD-L1, program cell death ligand-1; Q, every; Ctrough, trough concentration; %CV, (coefficient of variation) percent; AUC, area under the curve; ss, steady state; PFS, progression free survival; prep, preparation.